ENTA logo

ENTA
Enanta Pharmaceuticals Inc

1,166
Mkt Cap
$414.98M
Volume
188,173.00
52W High
$17.15
52W Low
$4.09
PE Ratio
-4.46
ENTA Fundamentals
Price
$14.51
Prev Close
$14.30
Open
$14.02
50D MA
$13.99
Beta
1.05
Avg. Volume
247,257.80
EPS (Annual)
-$3.84
P/B
3.28
Rev/Employee
$544,366.67
$267.58
Loading...
Loading...
News
all
press releases
What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock
Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·18d ago
News Placeholder
More News
News Placeholder
Equities Analysts Issue Forecasts for ENTA Q2 Earnings
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Research analysts at HC Wainwright raised their Q2 2026 EPS estimates for Enanta Pharmaceuticals in a report released on Tuesday, February...
MarketBeat·18d ago
News Placeholder
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +21.50% and +19.52%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·21d ago
News Placeholder
Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Beats Estimates By $0.12 EPS
Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) posted its earnings results on Monday. The biotechnology company reported ($0.42) earnings per share for the quarter, beating the consensus...
MarketBeat·21d ago
News Placeholder
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial...
Business Wire·21d ago
News Placeholder
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven research firms that are covering the firm, MarketBeat...
MarketBeat·1mo ago
News Placeholder
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections and immunological...
Business Wire·2mo ago
News Placeholder
Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains?
Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·2mo ago
News Placeholder
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven research firms that are presently covering the firm...
MarketBeat·2mo ago
News Placeholder
Enanta Pharmaceuticals (ENTA) Surges 5.9%: Is This an Indication of Further Gains?
Enanta Pharmaceuticals (ENTA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks·2mo ago
<
1
2
...
>

Latest ENTA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.